Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

Synagis is a former blockbuster – first approved ... However, revenues from the antibody are expected to drop sharply once Beyfortus and vaccines for RSV prevention enter the market.

While Robert F. Kennedy Jr., President Donald Trump’s pick to lead the US Department of Health and Human Services, has backpedaled on his anti-vaccine rhetoric during his Senate confirmation ...

KAMPALA, Feb 3 (Reuters) - Uganda has begun a trial vaccination programme for the strain of Ebola viral infection that is behind the country's latest outbreak, according to the World Health ...

Sobi has completed the acquisition of AstraZeneca’s Synagis (palivizumab) for $1.5 billion in cash and shares, plus certain conditional payments. As part of the deal, first announced in August ...

Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined Pediarix (GlaxoSmithKline) 24 hr Manufacturer Diphtheria and ...

The development and use of aquatic vaccines are the safest and most effective ways to prevent aquatic animal diseases and preserve the health and sustainability of aquaculture. To give references for ...

After hours: 7:56:20 pm GMT-5 ...